圣诺医药-B再涨超9% 华熙生物认购公司超9%股份 加码小核酸医美赛道

Core Viewpoint - Sanofi Pharmaceutical-B (02257) has seen a significant increase in its stock price, with a year-to-date rise exceeding 530%, currently trading at 22.06 HKD with a transaction volume of 29.72 million HKD [1] Group 1: Investment and Shareholding - Sanofi Pharmaceutical recently announced a placement of 17.35 million new shares at a discount of 19.84% to four investors, including Huaxi Biotechnology (Hong Kong) [1] - Huaxi Biotechnology plans to invest approximately 138 million CNY through its wholly-owned subsidiary, acquiring about 9.44% of Sanofi Pharmaceutical's shares post-placement [1] Group 2: Strategic Collaboration - The investment by Huaxi Biotechnology aims to advance Sanofi Pharmaceutical's research and commercialization in the fields of medical aesthetics, aging intervention, and regenerative medicine, particularly focusing on the STP705 targeted fat reduction project and other siRNA-based medical aesthetic assets [1] - Huaxi Biotechnology emphasizes its role not only as a financial investor but also as a strategic partner, indicating potential for further business collaboration between the two companies [1]